Navigation Links
New muscular dystrophy treatment shows promise in early study led by Children's National
Date:9/17/2013

g/research/faculty/bios/cgmr/nagaraju_k.aspx" target="_blank">Kanneboyina Nagaraju, DVM, PhD, the lead author of the study, and principal investigator in the Center for Genetic Medicine at Children's National. "It is becoming increasingly clear that membrane integrity and repair are crucial factors not only in muscle, but also in cardiovascular, neurodegenerative, and airway disorders. In-creasing pre-clinical data suggest that VBP15 may show efficacy in these other disorders and in many other indications where steroids are used." Dr. Nagaraju noted.

Initial clinical trials of VBP15 are planned, pending Food and Drug Administration (FDA) review and approval, anticipated in 2014. ReveraGen Biopharma, Inc., the first Children's National private spin-off company, is working closely with Children's National investigators to translate the pre-clinical findings to DMD patients. ReveraGen Biopharma collaborated with NIH/TRND on VBP15, which was selected through a national com-petitive process, one of the few inaugural compounds selected through this novel pro-gram.

"The partnership with NIH and support from many others is illustrative of the importance of private-public partnerships that are essential in expediting the development of orphan disease therapeutics," remarked Edward Connor, MD, CEO, and CMO of ReveraGen Biopharma and Director of Innovation Development at Children's National. "We are optimistic that the new drug will translate well to patients, and are moving this forward as quickly as possible, while assuring safety."


'/>"/>

Contact: Emily Hartman
ehartman@childrensnational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Combined therapy could repair and prevent damage in Duchenne muscular dystrophy
2. New drug improves walking performance for Duchenne muscular dystrophy patients
3. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
4. Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
5. Scientists discover needle in a haystack for muscular dystrophy patients
6. Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy
7. Stem-cell approach shows promise for Duchenne muscular dystrophy
8. Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
9. Another muscular dystrophy mystery solved; MU scientists inch closer to a therapy for patients
10. Protein injection points to muscular dystrophy treatment
11. Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... of iodine-125 (125I) in cancer treatment has been ... ganglia are critical for neural transmission between the ... and colleagues from Institute of Radiation Medicine, Chinese ... could be implanted into rat dorsal root ganglia ... seeds with different radioactivity (0, 14.8, 29.6 MBq) ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... nervous control of nematode mating behavior have produced video ... a hermaphrodite. Writing in the open access journal ... the California Institute of Technology investigated the role of ... achieve an exploratory embrace. The video shows ...
... and China have gathered in Barcelona this week to report ... data from ESA and Chinese Earth observation satellites. Dragon ... of Science and Technology (MOST) of China encourages scientists ... environmental phenomena in China. ,The symposium, held in Barcelona,s World ...
... Mo. If the growing presence of computer ,geeks, ... increasingly becoming essential tools for detecting and combating skullduggery. ... advantage of these tools. Researchers also are beginning to ... of deception, known as molecular mimicry. "Molecular ...
Cached Biology News:Europe and China watching Earth together 2Computers aid in cracking deception in plants 2
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
(Date:7/30/2014)... July 30, 2014  Replikins Ltd. today released new ... Ebola virus. Before the current outbreaks, the mean Ebola ... amino acids) between 1995 and 2002 was 1.1; the ... 2012, and sixteen-fold in 2013, thus predicting the current ... technology has been shown to be able to predict ...
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... (Amex: PLX ), announced today the pricing of ... stock at a,public offering price of $5.00 per share. ... to purchase up to 1,500,000 additional shares of,common stock ... is acting as sole book-running manager for this,offering. CIBC ...
... Oct. 24 , First Quarter Highlights:, - ... - Diluted EPS up 40% to $0.35 year-over-year, excluding ... related to one-time non-U.S. net tax adjustments PAREXEL ... results for the first quarter ended September 30, 2007. ...
... The Pittsburgh Life Sciences,Greenhouse (PLSG), the private/public ... a fast track for growth, announced that ... LLC, a developmental-stage,medical device company, whose goal ... probe that will alleviate the existing,limitations of ...
Cached Biology Technology:Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 9The PLSG Invests $115,000 in Innovention Technologies, LLC 2
... Tissue Extract Protein Array Kit is designed ... extracts. The expression of a protein in ... specific antibody. When the antibody binds the ... sensitive chemiluminescent or fluorescent signal created by ...
... is a is a bovine protein-free alternative ... is an aqueous solution that contains non-toxic ... saline), pH 6.6 - 7.2. This ... and 0.02% bromonitrodioxane as a preservative. ...
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
...
Biology Products: